

# Ranitidine Hydrochloride (CAS number- 66357-35-5)

TAJMTF-KNSDAR4875

Taj Active Pharmaceuticals Ingredients

[www.tajapi.com](http://www.tajapi.com)

Active Pharmaceutical Ingredients  
TAJ PHARMACEUTICALS LIMITED INDIA




Raw Material / Chemicals Index

Taj Pharmaceuticals Ltd.
<b>Ranitidine Hydrochloride</b>
(Cas No 66357-35-5)

**Ranitidine Hydrochloride**  
CAS number 66357-35-5

**Structure :**



Systematic (IUPAC) name

N-(2-[[5-[(dimethylamino)methyl]furan-2-yl)methylthio]ethyl]-N-methyl-2-nitroethene-1,1-diamine

**Chemical Name:** N-[2-[[5-[(dimethylamino)methyl]furfuryl]thio]ethyl]-N'-methyl-2-nitrovinylidenediamine monohydrochloride

**Classification:** Antagonist to histamine H<sub>2</sub> receptors

**Molecule:** C<sub>13</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>S · HCl

**Molecule Weight:** 350.87

**Quality Standard:** EP5/USP31

**Identifiers**

CAS number 66357-35-5  
ATC code A02BA02  
PubChem 3001055  
DrugBank APRD00254  
ChemSpider 571454

#### **Chemical data**

Formula C<sub>13</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>S  
Mol. mass 314.4 g/mol

#### **Pharmacokinetic data**

Bioavailability 39 to 88%  
Metabolism Hepatic  
Half life 2–3 hours  
Excretion 30–70% Renal

#### **Biological Activity**

Potent, selective and competitive histamine H<sub>2</sub> receptor antagonist (pA<sub>2</sub> = 6.95-7.2). In vivo, inhibits gastric acid secretion induced by histamine, pentagastrin, bethanecol and food. Also inhibits aspirin-induced gastric lesions.

#### **Solubility & Usage Info:**

Water to 50 mM  
Ethanol to 25 mM  
DMSO to 25 mM

**Description:** Potent, selective and competitive histamine H<sub>2</sub> receptor antagonist (pA<sub>2</sub> = 6.95-7.2). In vivo, inhibits gastric acid secretion induced by histamine, pentagastrin, bethanecol and food. Also inhibits aspirin-induced gastric lesions.

#### **Physical and Chemical Properties:**

Batch Molecular Formula: C<sub>13</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>S.HCl  
Batch Molecular Weight: 350.86  
CAS Number: [66357-35-5]  
Physical Appearance: Pale yellow solid  
Batch Molecular Structure:

**Stability Advice:** Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath). Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard

#### **recommendations are:**

**SOLIDS:** Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

**SOLUTIONS:** We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20° C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

## **6. TOXICOLOGICAL INFORMATION**

To the best of our knowledge, the chemical, physical and toxicological properties have not been fully investigated.

**RTECS No:** KM6556500

**Target Organs:** Eyes; Respiratory system; Skin; Central nervous system;  
Cardiovascular system; Digestive system;

**Toxicity Data:** ORL-MAN TDLO: 4286µg/kg; ORL- WMN TDLO:  
12mg/kg; ORL-RAT LD50: >5gm/kg; IVN-RAT LD50:  
93mg/kg; IMS-RAT LD50: 2018mg/kg; ORL-MUS LD50:  
884mg/kg; IVN-MUS Ld50: 80mg/kg; IMS-MUS LD50:  
280mg/kg; IPR-MUS TDLo: 570mg/kg.

Only selected Registry of Toxic Effects of Chemical Substances (RTECS) data is presented above. See actual entry in RTECS for complete information.

#### **Transport Information**

U.N.Number:  
Proper Shipping Name:  
IATA Class:  
IATA Packing Group:

### Fire-Fighting Measures

Extinguishing Media: Material is non-combustible. Use extinguishing media appropriate to surrounding fire conditions.  
Unusual Fire and Explosive Hazards: May emit toxic gases upon thermal decomposition. Special Fire-Fighting Procedures: Wear protective clothing to prevent contact with skin and eyes.

### Accidental Release Measures

Wear appropriate protective clothing. Cover spillage with suitable absorbent material. Using non-spark tools, sweep up material and place in an appropriate container. Decontaminate spill site with 10% caustic solution and ventilate area until after disposal is complete. Hold all material for appropriate disposal as described under DISPOSAL CONDITIONS.

### Disposal Conditions

As specific country, federal, state and local environmental regulations are varied and change frequently, we recommend that you contact your local department for Health Services for information on the correct disposal of this product.

**Handling and Storage** Use in a chemical fume hood, with air supplied by an independent system. Avoid inhalation, contact with eyes, skin and clothing. Avoid prolonged or repeated exposure.

Material should be stored in a tightly sealed container under the storage condition stated on the Product Information sheet and on the vial label.

### Hazards Identification

RTECS substance category: Drug Exposure may cause irritation to eyes, mucous membranes upper respiratory tract and skin. Exposure may also cause the following: Rigidity, includes catalepsy; Muscle contraction or spasticity; Increased pulse rate; Jaundice and impaired liver function; Degenerative changes in brain coverings; Effect on specific coenzymes.

**Brittain and Daly** (1981) A review of the animal pharmacology of ranitidine - a new, selective histamine H<sub>2</sub>-antagonist. Scand.J.Gastroenterol.Suppl. **69 1**. **Daly** et al (1981) Some in vitro and in vivo actions of the new histamine H<sub>2</sub>-receptor antagonist, ranitidine. Br.J.Pharmacol. **72 49**. **Daly** et al (1981) Antagonism of vasodepressor and gastric secretory responses to histamine by the H<sub>2</sub>-receptor antagonists, ranitidine and cimetidine, in the anaesthetized dog. Br.J.Pharmacol. 72 55.

We have experience in Exporting and Manufacturing of all Countries and Overseas medicines in quick reliable manner and we are very interested to start collaboration with your company or organisation!



2004 - 2010 Taj Pharmaceuticals Limited. All rights reserved

Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Ltd products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider. Active Pharmaceutical Ingredients manufacturer, exporter, drug ingredients, pharmaceuticals, India

Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to\*\*\*\*